Five recombinant a interferons and two recombinant 13 interferons have been tested for their ability to inhibit yields of herpes simplex virus types 1 and 2 and human cytomegalovirus in human embryonic lung cells. All of the a species and both of the 13 forms (cysteine and serine) were active against the herpesviruses tested in this study. Neither the recombinant a nor the recombinant 13 interferons exceeded the activity of the native species against herpes simplex viruses types 1 and 2. However, the recombinant 13 interferons inhibited cytomegalovirus more than either the native 13 or the a interferon species with the exception of interferon aK (a6).
The use of a natural antiviral substance such as interferon, either alone or in combination with synthetic drugs, may have a place in the treatment of herpesvirus infections. This idea is supported by the recent successful modification of both herpes simplex virus (HSV) and human cytomegalovirus (CMV) infections with interferon, as reviewed recently by Hirsch and Schooley (5) . Through the use of recombinant DNA techniques, it has become possible to isolate and express in bacteria some of the individual molecular species of human interferons (2, 11). There are 13 or more nonallelic interferon a genes but only 1 gene for interferon 3. There is some evidence that the translation products may have distinct antiviral properties (10) . The purpose of the following investigation was to compare the antiviral activities of recombinant a and P interferons with those of native a and 13 types against two human herpesviruses.
The cultivation and assay of HSV for PFU on Vero cells has been described previously (8) . CMV (AD169) was propagated and assayed in human embryonic lung cells as previously described (9) .
Partially purified recombinant ax and P interferons were supplied by Cetus Corp., Emeryville, Calif. The species designations given by Cetus Corp. and their corresponding forms described by Genentech and Pestka (7) and by Weissmann et al. (11) are as follows, respectively: al, D, al; a6L, L, alO; a54, K, a6; a61, G, a5; and a76, no designation, a4a, b. Both the Cetus and Weissmann al species differ from the D species by the same single amino acid. The native interferon 13 molecule has three cysteine residues in the molecule ( cys). Another form has serine substituted for cysteine at position 17 of the molecule (13 ser) (D. Mark, S.
Lu, A. Creasey, R. Yamamoto, and L. S. Lin, Proc. Natl. Acad. Sci. U.S.A., in press). Human leukocyte interferon a (oa-Cantell) was supplied by Kari Cantell, and human fibroblast interferon 1 (1-Tan) was supplied by C. Tan. The specific activities of all recombinant subtypes were ca. 108 U/mg; the specific activities of the a-Cantell and 1-Tan native species were both 107 U/mg. The antiviral titers of the a species, as measured by vesicular stomatitis virus plaque reduction (6) , were between 105 and 106 U/ml, and those of the 1 species were 106 U/ml. * Corresponding author.
Yield inhibition assays were used to quantitate antiviral activity of interferons against human herpesviruses. Human embryonic lung cells grown in multidish (35 mm) cultures were treated overnight with the human interferons diluted in Dulbecco minimal essential medium with 10% fetal calf serum. Drained cultures were infected by adsorbing virus for 2 h and then maintained with Dulbecco minimal essential medium with 1% fetal calf serum. For HSV, a multiplicity of infection of 0.1 was used for all experiments, and cultures were incubated for 14 h (approximately one cycle of virus replication) before harvest. Infected cultures were harvested by freezing at -70°C. The thawed cell extracts were clarified by low-speed centrifugation before assay of PFU yields. For CMV yield inhibition assays, an input multiplicity of 0.01 was used, and virus was allowed to replicate for 10 to 12 days. Infected cultures were harvested by scraping cells from culture vessels in the supernatant and then sonicating to disrupt cells. Samples were frozen at -70°C until assay for PFU.
Inhibition of yields of HSV types 1 and 2 and CMV by five recombinant interferon a and two recombinant interferon 1 species is summarized in Table 1 . Native a. and 13 species are included for comparison. Virus yield inhibition at each dose level was analyzed statistically by the Mann-Whitney twosample test. The significance levels at each dose were then combined to give a single significance level by the Fisher method of combination. The a and 1 species were comparable with the native forms for inhibition of yields of HSV types 1 and 2. However, a4 was significantly less effective (P < 0.05) than the other species tested. Both recombinant B species (cys and ser) reduced CMV yields more than most of the other interferons (P < 0.05) except aK. As with HSV types 1 and 2, a4 was minimally inhibitory to CMV replication even at doses of 1,000 U.
We have demonstrated that cloned recombinant interferon a and 13 species are both active against HSV types 1 and 2 and human CMV in vitro. However, there are differences between inhibitory effects of different species of recombinant interferon and between effects on different types of herpesviruses used as challenge. For example, interferon ax4 was only weakly effective as compared with other ao species in inhibiting both HSV and CMV. These results are in agreement with those of Fish et al. (3, 4) , who showed that (10) . It is of interest that both of the recombinant 1 interferons were more inhibitory to CMV than the ai species. The fact that 1 interferons acted more reproducibly than a on virus replications may relate to the idea that interferons act most efficiently in tissues similar to those from which they were derived (1). The interexperimental variations observed with most of the a but none of the ,B species used in this study could not be attributed to instability of the preparations. Titers of stored portions of all of these interferon species did not change significantly throughout the period of this study.
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